Amphastar Pharmaceuticals, Inc. (AMPH) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Amphastar Pharmaceuticals’s revenue went from $255M in fiscal 2016 to $720M in fiscal 2025, growth of about 12.2% a year.
Net income in fiscal 2025 was $98M, a net margin of 13.6%; the best year in this period was 2024 with $160M.
Over the twelve months to September 30, 2026, revenue was $746M and net income $99M.
Free cash flow was $121M in fiscal 2025 and positive in 9 of the 10 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $746M | $720M | $732M | $644M | $499M | $438M | $350M | $322M | $295M | $240M | $255M |
| Gross profit | $349M | $356M | $374M | $351M | $249M | $200M | $143M | $132M | $107M | $91M | $104M |
| Operating income | $140M | $140M | $205M | $197M | $107M | $70M | $11M | -$39000 | -$9M | -$1M | $15M |
| Net income | $99M | $98M | $160M | $138M | $91M | $62M | $1M | $49M | -$6M | $4M | $10M |
| EPS (diluted) | $2.19 | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 | $0.03 | $0.98 | $-0.12 | $0.08 | $0.21 |
| R&D | $92M | $86M | $74M | $74M | $75M | $61M | $67M | $69M | $58M | $44M | $42M |
| Revenue growth | — | −1.7% | +13.6% | +29.1% | +14.0% | +25.1% | +8.5% | +9.4% | +22.7% | −5.9% | +1.5% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $175M | $156M | $213M | $184M | $89M | $98M | $57M | $42M | $38M | $39M | $39M |
| Capital spending | -$36M | -$35M | -$41M | -$38M | -$24M | -$27M | -$34M | -$42M | -$47M | -$35M | -$21M |
| Free cash flow | $139M | $121M | $172M | $145M | $65M | $71M | $23M | $207000 | -$9M | $4M | $17M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $96M | $76M | $85M | $58M | $40M | $29M | $24M | $22M | $25M | $31M | $10M |
| Stock-based pay | $30M | $27M | $24M | $20M | $18M | $19M | $20M | $17M | $17M | $17M | $15M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $283M | $222M | $257M | $176M | $137M | $106M | $85M | $89M | $68M | $73M |
| Debt | — | $667M | $662M | $637M | $106M | $108M | $79M | $74M | $67M | $52M | $41M |
| Equity | — | $789M | $732M | $639M | $529M | $446M | $402M | $381M | $332M | $334M | $329M |
| Total assets | — | $1.6B | $1.6B | $1.5B | $742M | $672M | $631M | $587M | $514M | $451M | $428M |
| Shares (diluted) | 43M | 48M | 52M | 53M | 52M | 50M | 49M | 50M | 46M | 48M | 48M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 46.8% | 49.5% | 51.1% | 54.5% | 49.9% | 45.6% | 41.0% | 40.9% | 36.3% | 37.7% | 40.8% |
| Operating margin | 18.7% | 19.5% | 28.1% | 30.6% | 21.5% | 16.0% | 3.1% | -0.0% | -2.9% | -0.5% | 6.0% |
| Net margin | 13.3% | 13.6% | 21.8% | 21.3% | 18.3% | 14.2% | 0.4% | 15.2% | -1.9% | 1.5% | 3.9% |
| FCF margin | 18.6% | 16.8% | 23.5% | 22.6% | 13.1% | 16.1% | 6.7% | 0.1% | -2.9% | 1.7% | 6.7% |
| ROIC | — | 7.6% | 12.4% | 12.6% | 13.5% | 9.5% | 1.8% | -0.0% | -1.5% | -0.3% | 2.8% |
| ROE | — | 12.4% | 21.8% | 21.5% | 17.3% | 13.9% | 0.4% | 12.8% | -1.7% | 1.1% | 3.0% |
Frequently asked questions
What is Amphastar Pharmaceuticals’s annual revenue?
$720M in fiscal 2025 and $746M over the twelve months to September 30, 2026.
How much profit does Amphastar Pharmaceuticals make?
Net income was $98M in fiscal 2025 (net margin 13.6%).
Is Amphastar Pharmaceuticals’s revenue growing?
No: revenue fell 1.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.